Key clinical point: MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated renal cell carcinoma (RCC) and nonrenal lesions.
Major finding: The overall response rate in target RCC lesions was 36.1%, with unconfirmed partial responses in 11.5%, stable disease in 62.3%, and progression in no target lesions. At a median follow-up of 68.7 weeks, the median duration of response was not reached.
Study details: A phase 2 study of 61 treatment-naive patients with Von Hippel-Lindau disease-associated RCC treated with 120 mg daily of MK-6482.
Disclosures: The study was funded by Merck Sharp & Dohme Corp. Dr. Srinivasan disclosed funding from Merck and Calithera Biosciences.
Srinivasan R et al. ESMO 2020. Abstract LBA26.